A Case of Primary Hepatic Burkitt's Lymphoma.
- Author:
Seung Hyun LEE
1
;
Hyung Joon KIM
;
Jang Sik MUN
;
Hyoung Chul OH
;
Hyun Woong LEE
;
Chang Hwan CHOI
;
Jeong Wook KIM
;
Jae Hyuk DO
;
Jae Gyu KIM
;
Sae Kyung CHANG
;
Mi Kyung KIM
Author Information
1. Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea. mdjoon@cau.ac.kr
- Publication Type:Case Report
- Keywords:
Primary hepatic lymphoma;
Burkitt's lymphoma
- MeSH:
Antimetabolites, Antineoplastic/therapeutic use;
Burkitt Lymphoma/*diagnosis/drug therapy/pathology;
Combined Modality Therapy;
Cytarabine/therapeutic use;
Diagnosis, Differential;
Humans;
Liver Neoplasms/*diagnosis/drug therapy/pathology;
Male;
Methotrexate/therapeutic use;
Tomography, X-Ray Computed;
Young Adult
- From:The Korean Journal of Gastroenterology
2008;51(4):259-264
- CountryRepublic of Korea
- Language:English
-
Abstract:
Burkitt's lymphoma is a rare disease that belongs to the aggressive non-Hodgkin's lymphoma. Herein, we report a case of primary hepatic Burkitt's lymphoma. A 19-year-old man visited the hospital for right upper quadrant pain. He felt fatigue for two months. Physical examination revealed hepatomegaly and no palpable lymph node. He had no fever, weight loss, or night sweating. Laboratory finding showed mild anemia (hemoglobin, 12.4 g/dL), mild elevated transaminase (ALT, 52 IU/L), elevated lactate dehydrogenase (LDH, 437 IU/L), and alkaline phosphatase (ALP, 129 IU/L). The viral marker was positive for HBsAg, HBeAg, anti-HBs, and anti-HBc (IgG), and negative for anti-HBe, anti-HCV, and anti-HIV. CEA, AFP, and CA19-9 levels were within normal ranges. The HBV DNA quantitation was 1.3x10(9) copies/ml. Abdominal-Pelvis CT scan and abdominal MRI finding were compatable with malignant lymphoma. Liver biopsy examination confirmed Burkitt's lymphoma. No metastasis was detected in the thoracic cavity, bone marrow, and spinal fluid. The patient was treated with the combination regimen of cyclophosphamide, doxorubicin, vincristine, prednisone and high dose methotrexate. Cytosine arabinoside and methotrexate were added for CNS prophylaxis by intrathecal installation. Chemotherapy was administered every 3 weeks for fifteen cycles. Serial follow-up CT scan showed a marked decrease in the size of hepatic lesions. Follow-up CT scan and PET-CT scan were perfomed 4 weeks after the final cycle disclosed no definite residual or active lesion confirming the state of complete remission.
